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Abstract
Background: Alcohol use disorder (AUD) leads to a significant individual and societal burden. To achieve higher
therapy success rates, therapeutic interventions still need to be improved. Most current neuroscientific
conceptualizations of AUD focus on the imbalance between an enhanced automatic reaction to alcohol cues and
impaired inhibition. Complementary to traditional relapse prevention strategies, novel computerized training
interventions aim to directly alter these processes. This study tests a computerized alcohol-specific inhibition
training in a large clinical sample and investigates its effects on behavioral, experimental and neurophysiological
outcomes. It also analyzes whether variations in inhibition difficulty and/or endogenous cortisol levels during
training impact these effects.
Methods: This is a double-blind, randomized controlled trial (RCT) with 246 inpatients with AUD participating. After
baseline assessment, participants are randomly assigned to one of three computerized Go-NoGo-based inhibition
training interventions (two alcohol-specific versions with different Go/NoGo ratios, or neutral control training) and
one of two intervention times (morning/afternoon), resulting in six study arms. All patients perform six training
sessions within 2 weeks. Endogenous cortisol is measured in 80 patients before and after the first training session.
Inhibitory control and implicit associations towards alcohol are assessed pre and post training, at which point
electroencephalography (EEG) is additionally measured in 60 patients. Patients’ alcohol consumption and relevant
psychological constructs (e.g., craving, self-efficacy, treatment motivation) are measured at discharge and at 3-, 6-
and 12-month follow-ups. Fifty healthy participants are assessed (20 with EEG) at one time point as a healthy
control group.
Discussion: This study investigates the effects of a computerized, alcohol-specific inhibition training for the first
time in patients with AUD. Results should give insight into the effectiveness of this potential add-on to standard
AUD treatment, including proximal and distal measures and effects on behavioral, experimental and
neurophysiological measures. Information about working mechanisms and potential optimizations of this training
are gathered through variations regarding difficulty of inhibition training and training time. This study may thus
contribute to a deepened understanding of AUD and the improvement of its evidence-based treatment.
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Background
Alcohol use disorder (AUD) is a major public health
problem which has a substantial impact on patients’
psychological, physiological and social functioning [1–
4]. Severe AUD often remains a lifelong condition
due to patients’ susceptibility to relapse [5–7]. Despite
the development of valuable treatment programs [8,
9], one third of patients relapse within 1 year after
treatment, highlighting the need for effective new in-
terventions to be added to these programs.
Current models of substance use disorders (SUDs)
are based on neuroscientific research into subcortical
alterations (e.g., [10–12]) and psychological investiga-
tions on implicit processes [13], and postulate on an
imbalance between subcortical, implicit processes and
cortical control processes. Briefly, these models as-
sume that automated (subcortical) cue-reactivity is
enhanced, thus leading to a strong drive to consume,
while the opponent (cortical) executive control is
weakened, making it difficult to inhibit this impulse
(e.g., [11, 14–16]). The neuroscientific findings that
underlie these models include enhanced reactivity to
substance-related cues in brain regions related to re-
ward prediction and saliency processing (e.g., nucleus
accumbens, amygdala), habits and motivation (dorsal
striatum, orbitofrontal cortex) and alterations in brain
regions related to inhibitory control (dorsolateral pre-
frontal cortex, inferior frontal cortex and anterior cin-
gulate cortex) [17, 18]. There is an extensive body of
literature indicating that SUD is associated with im-
paired performance in inhibitory control tasks [19–
24]. Until recently, these tasks did not differentiate
between inhibition in a substance-related versus neu-
tral context. However, this distinction seems to be
clinically relevant, given that the central malfunction
leading to relapse is the inability to exert inhibitory
control in a substance-related context. Recent studies
have suggested that alcohol-related inhibition de-
mands additional neuronal resources in patients with
AUD and heavy drinkers [25–28].
To translate the findings of impaired inhibitory control
and enhanced cue-reactivity into a therapeutic context,
an inhibition training for eating disorders [29–31] has
been adapted into a novel alcohol-specific inhibition
training and introduced into the field of AUD research
[32, 33]. During this short, computerized, behavioral
training, alcohol-related stimuli are consistently paired
with a stopping response. Such an intervention might
thus improve inhibitory control by training it on an ex-
plicit as well as a habitual level and possibly reduce cue-
reactivity through stimulus devaluation.
The effect of one or two of these training sessions on
alcohol consumption has been tested in regular drinkers
[34, 35] and non-clinical, heavy drinkers [32, 33, 36, 37].
When alcohol consumption was assessed immediately
after the training session, two studies found decreased
consumption [35, 36], one study observed a non-
significant trend in that direction [33], another study re-
ported longer latency until participants took the first sip
[37], and one study found no effects [34]. Of those stud-
ies assessing alcohol consumption 1 or 2 weeks post
intervention, three studies reported decreased consump-
tion after alcohol-specific inhibition training [32, 33, 37].
Note, however, that in two of these studies, the interven-
tion was compared to a control condition, which could
potentially have fostered alcohol consumption within the
control group [32, 33]. Two other studies found no sig-
nificant effects [34, 35]. In summary, while the effects of
this training are inconsistent in non-clinical samples, it
might be more effective in clinical populations where (1)
the motivation to change drinking behavior is higher
and (2) the impairment targeted by the training is as-
sumed to be more pronounced at baseline. Therefore, it
is important to test the feasibility and efficacy of the
training in clinical populations with AUD. The present
randomized controlled, double-blind study aims to close
this gap, and includes follow-up measurements of drink-
ing behavior and related concepts up to 12 months after
treatment discharge, allowing assessment of potential
clinically relevant long-term effects.
There are two putative working mechanisms by which
alcohol-specific inhibition training is thought to be ef-
fective. The first is through enhancing inhibitory capaci-
ties in the context of alcohol-related cues, which can be
assessed with inhibitory tasks, such as the Go-NoGo
Task (GNG) or the Stop-Signal Task (SST). The second
putative working mechanism regards devaluation of the
stimuli. It is based on the Behavior Stimulus Interaction
Theory [38], which states that the repeated stopping re-
sponse to the rewarding (alcohol, in this context) stimuli
causes a devaluation thereof [31, 33]. This mechanism is
thus thought to alter the automatically attributed appeal
of alcohol-related stimuli, an effect which can be mea-
sured with the Implicit Association Test (IAT).
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With respect to the devaluation mechanism, the first
two studies were consistent with predictions of the Behav-
ior Stimulus Interaction Theory in their reports that par-
ticipants’ implicit attitudes shifted towards a more
negative evaluation of alcohol-related stimuli after
alcohol-specific inhibition training [32, 33]. However, this
finding could not be replicated in the four subsequent
studies [34–37].
In regard to an inhibition-related working meachanism,
those studies using the respective measures found no ef-
fects of GNG-based inhibition training on an SST [32, 37]
nor flanker task [34]. However, these tasks measure
slightly different inhibitory aspects (e.g., action
cancellation in case of the SST) than the one affected dur-
ing the GNG-based training (action restraint). The only
study which assessed inhibitory functioning in the same
form as targeted during training (i.e., measurement of in-
hibitory control with a GNG after a GNG-based training)
reported no effects on reaction times during Go trials. Un-
fortunately, data on errors of commission (EOCs), which
are a commonly used indicator of inhibitory capacities
and an essential and proximal experimental outcome of a
GNG-based inhibition training, were not reported in this
study [36] and are thus still missing. Another important
aspect concerns Go/NoGo ratio incorporated during
training sessions. With one exception [34], most studies
emloyed equiprobable GNG tasks with a Go/NoGo ratio
of 50/50 during the training session. Such a ratio is un-
usually balanced for GNG tasks, where NoGo responses
usually only make up 10–20% of the trials (e.g., [23, 24,
39]) in order to establish a high tendency to respond while
making inihibition more demanding. Thus, it is possible
that these versions failed to create the context of a prepo-
tent Go response, in which inhibition could effectively be
trained. The present study aims to extend prior research
on potential working mechanisms by comparing two ver-
sions of this alcohol-specific inhibition training differing
solely in the Go/NoGo ratio (thus in inhibition difficulty)
and by comparing these versions’ effects on inhibitory
capacities as well as on implicit associations.
With regard to other clinically important psychological
variables, research has shown that outcome expectancies
[40], self-efficacy to remain abstinent [41], motivation to
change alcohol use [42] and craving [43] predict drink-
ing outcomes at 1-year follow-up. These variables might
thus act as potential mediators of effects in a clinical
study. Furthermore, if the alcohol-specific inhibition
training influences implicit associations towards alcohol,
it might also affect explicit expectancies and/or subject-
ive craving. The present study will, therefore, include
these variables as potential outcomes and mediators in
explorative analyses.
Taken together, the present study investigates the effects
of an alcohol-specific inhibition training for the first time
in a clinical sample using a randomized controlled,
double-blind design with long follow-up periods. In doing
so, the study contributes to research on potential working
mechanisms by comparing two versions of the training
which differ only in the Go/NoGo ratio and by the com-
parison of their effects on inhibitory functions and implicit
associations. Explorative analyses will target psychological
variables, such as craving, outcome expectancies, self-
efficacy and motivation to change alcohol use. As the
training’s rationale is anchored in neuroscientific research,
we will also monitor neurophysiological effects with
multi-channel electroencephalography (EEG) in order to
investigate whether the training changes the neurophysio-
logical correlates of alcohol-specific inhibition and/or im-
plicit associations. Finally, prior research has shown that
endogenous cortisol is a consolidation enhancer [44],
which peaks in the morning [44, 45] and has been shown
to improve effects of other learning-based therapies [46].
Since training procedures rely on learning processes af-
fected by endogenous cortisol, we are, therefore, interested
in whether its levels influence training effects.
Study aim
In the present project, the Inhibition Training (INTRA)
study, 246 recently abstinent patients with AUD attend-
ing an inpatient treatment program will be randomly
assigned to one of two alcohol-specific inhibition train-
ing groups (each with a different Go/NoGo ratio) or to a
control group. Our aim is to examine whether variations
of inhibition training have a positive effect on drinking
behavior, implicit attitudes, and neurophysiological re-
activity to alcohol-related stimuli. Thus, a subgroup of
patients will additionally undergo EEG recording before
and after the intervention so that neurophysiological ef-
fects of the training can be assessed and related to clin-
ical outcomes. In addition, 50 healthy controls (with
EEG measurement of 20) will be assessed once to com-
pare patients’ pre-training data. Since training effects
rely on learning processes, the influence of endogenous
cortisol level (a consolidation enhancer, which peaks in
the morning and decreases in the course of the day [44])
on training outcome will be investigated by varying the
time of day in which the training is performed. All pa-
tients’ inhibition and implicit associations towards alco-
hol will be measured immediately before and after the
training. We will also measure the training’s effects on
proximal outcome variables (e.g., implicit associations,
inhibitory control, abstinence-related self-efficacy, crav-
ing) post training, and distal outcome variables (e.g., per-
centage of days abstinent – PDA; heavy-drinking days –
HDD; and time to first drink – TFD) at 3-, 6- and 12-
month follow-ups.
For the first time, this trial will investigate the thera-
peutic potential of an alcohol-specific inhibition training
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as a therapeutic supplement in a sample with patients
suffering from severe AUD. In doing so, the impact on
training efficacy of time of training and Go/NoGo ratio
will additionally be investigated and the underlying
neurophysiological mechanisms of the training eluci-
dated. Moreover, potential AUD-related psychological
constructs will be explored. The project thus aims to
contribute to the improvement of the evidence-based
treatment of AUD.
Research questions
Based on prior research, the following five research
questions are examined:
1. Does the alcohol-specific inhibition training (Alc-IT,
compared to the control intervention) reduce PDA
and HDD and/or extend the time to first drink
(TFD) at 3-months’ follow-up (primary outcomes)?
2. What is the effect of the Alc-IT on behavioral
experimental parameters?
(a) Does Alc-IT decrease positive implicit associa-
tions compared to the control training?
(b) Does Alc-IT enhance response inhibition com-
pared to the control training?
3. Are the neurophysiological correlates of alcohol-
specific inhibition and implicit associations towards
alcohol changed by Alc-IT?
4. Does endogenous cortisol moderate the effect of
the Alc-IT?
5. In addition, explorative questions investigate whether
the effects of the training on outcomes are mediated
by AUD-related psychological constructs, such as
alcohol-related self-efficacy, craving or motivation
Methods
Study design and setting
The present study is a multicenter, double-blind, random-
ized controlled trial (RCT) with six conditions. The inter-
ventions consist of two alcohol-specific inhibition
trainings (with different Go/NoGo ratios) and one control
inhibition training that is not context specific. In each ver-
sion of the training, six sessions will be performed over
the space of 2 weeks. Next to the three versions of the
training, different samples will perform the training in dif-
ferent times of the day (morning/afternoon), resulting in a
total of six conditions. Between the three study sites, 246
abstinent inpatients with AUD will be recruited. To com-
pare our patient sample to the healthy population, we will
measure 30 (behavioral) and 20 (EEG) healthy participants
at one point in time. The duration of the study from the
first inclusion to the last participant’s follow-up is 36–40
months. Recruitment, randomization, and baseline mea-
surements (T1) will take place at one of the three study
sites at the beginning of the regular inpatient program. All
patients will have undergone detoxification prior to enter-
ing this inpatient program. Pre-training assessment (T2) is
usually performed by the end of the second week or at the
beginning of the third week of the inpatient stay and is
followed by the 2 weeks, during which the six training ses-
sions of the intervention or the control training are per-
formed. Post-training assessment (T3) takes place 1 to 4
days after the last training session. At discharge (T4), the
last measurement during inpatient program is performed.
The duration of the inpatient stay typically varies between
8 and 12weeks, depending on individual and institutional
factors. Follow-up assessments take place 3 (T5), 6 (T6)
and 12 (T7) months after discharge and consist of a
questionnaire battery and a telephone interview (see also
“Procedure” and Fig. 1).
Participants
Patients
We will screen all patients who previously completed a
detoxification and then entered an alcohol-specific in-
patient treatment program at one of three specialized
addiction treatment centers in Switzerland, namely the
Suedhang Hospital (Bern); the Forel Hospital (Zuerich)
and the Psychiatric Hospital of Muensingen (Bern). In-
clusion criteria are age 18–60 years and abstinence
from alcohol for at least 4 weeks prior to the first train-
ing session. Exclusion criteria are other main psychi-
atric diagnoses than AUD (comorbidities are allowed as
long as AUD is considered to be the main diagnosis),
other severe SUD (except nicotine; Drug Use Identifica-
tion Test (DUDIT [47, 48]) ≥ 25 per substance), no di-
agnosed neurocognitive problems (e.g., Korsakoff
syndrome) in the medical history, current medical con-
ditions preventing participation (e.g., acute infectious
diseases), the inability to read and understand the par-
ticipant’s information and the enrollment of an investi-
gator, their family members, employees and other
dependent persons. Written informed consent will be
obtained from all patients at the beginning of the study.
Healthy controls
In order to compare behavioral data of the patient sample
to that of a healthy population, 50 healthy controls will be
measured at one point of time (20 with EEG). Inclusion
criteria for healthy controls are age 18–60 years, non-
problematic drinking behavior (Alcohol Use Disorders
Identification Test (AUDIT [49]) < 8; Alcohol Use Dis-
order Scale (AUD-S [50]) < 2)), and no signs of psycho-
pathology (Brief Symptom Check List (BSCL [51, 52],)
GSIt-value ≤ 63). Exclusion criteria consist of current treat-
ment for a psychiatric diagnosis and/or psychopharmaco-
logical medication, treatment for SUD in the past,
problematic substance use (except nicotine; DUDIT ≥8
per substance, e.g., cannabis), neurocognitive problems,
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poor health conditions, the inability to read and under-
stand the study information. In the substudy EEG, add-
itional exclusion criteria are the occurrence of AUD in
first-degree relatives and hearing impairments. Written in-
formed consent will be obtained from all healthy controls
prior to inclusion. For a tabular overview of all in- and ex-
clusion criteria, see Additional file 1.
Stimulus material
Stimuli for training, GNG and IAT
A total of 40 pictures of alcoholic beverages, water and
neutral objects were created by the study team. All pic-
tures were photographed with a high-resolution camera
(Nikon D810, Nikon Inc., Tokyo, Japan) in a neutral set-
ting with a white background and the same light condi-
tions (two spotlights). Water pictures are the same for
all participants, whereas alcohol pictures will be matched
to the individual’s drink of choice. For this purpose,
three sets with either beer (seven lager, one wheat), wine
(two red, two white, two rosé, two sparkling wines) or
spirits (two vodka, two whiskey, two liquor, one gin, one
tequila) were generated. Each of the four beverage sets
includes eight pictures of brands commonly consumed
in Switzerland, with all pictures comprising a bottle or
can and a full beverage-specific glass (for examples, see
Additional file 2).
The eight neutral stimuli are everyday objects (e.g., a
flashlight plus battery) and were selected by complexity,
shape and familiarity. All pictures were edited with
GIMP software (GIMP 2.8.18, retrieved from https://
www.gimp.org) and adjusted for size, centralization,
brightness and background to ensure picture similarity.
Stimuli for SST
For the third task, stimulus material consist of 16 pictures
(344 × 400 pixel) of a database and are characterized by
Treatment admission
Baseline assessment (T1)
Diagnostics
Qs, TLFB
morning (n = 41) afternoon (n = 41)
Version 2: Alc-IT (75/25)
Alcohol-specific Inhibition Training 
75% Go, 25% NoGo
Pre-training assessment (T2)
GNG, IAT, SST
Qs
Post-training assessment (T3)
GNG, IAT, SST
Qs
Discharge assessment (T4)
Qs
3-month follow-up (T5)
Qs, TLFB
12-month follow-up (T7)
Qs
Inclusion
morning (n = 41) afternoon (n = 41)
Version 1: Alc-IT (50/50)
Alcohol-specific Inhibition Training 
50% Go, 50% NoGo
6-month follow-up (T6)
Qs
Randomization
morning (n = 41) afternoon (n = 41)
Version 3: Control Training
Non-specific Inhibition Training 
50% Go, 50% NoGo
In
p
at
ie
n
t
tr
ea
tm
en
t
F
o
llo
w
-u
p
1
24-26
12-13
1-2
2
12-13
~3-7+
Time lag 
(in weeks) 
morning (n = 41) afternoon (n = 41)
Version 1:  Alc-IT (50/50)
Training (6 sessions)
morning (n = 41) afternoon (n = 41)
Version 2:  Alc-IT (75/25)
Training (6 sessions)
morning (n = 41) afternoon (n = 41)
Version 3:  Control Training
Training (6 sessions)
Substudy EEG (n = 60)
EEG measurement
Substudy EEG (n = 60)
EEG measurement
Fig. 1 Study design of the INTRA study. Note that for the cortisol substudy, salvia-cortisol samples will be collected before and after the first
training session. Alc-IT alcohol-inhibition training, EEG electroencephalography, GNG Go-NoGo Task, IAT Implicit Association Test, INTRA Abbreviation of
the study name: INhibition TRaining in Alcohol use disorder, n sample size, SST Stop-Signal Task, TLFB Timeline-follow-back, Q questionnaire
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their alcohol relatedness, valence, craving, arousal, lumi-
nance, colors and visual complexity [53]. Four pictures of
each drink of choice (beer, wine and spirits), shot in (so-
cial) daily situations within a building, and four pictures of
everyday objects (e.g., a hydrant) located outdoors, were
selected. This additional stimulus material was chosen to
test for generalization of the effect of our intervention to a
novel inhibition task and to new stimuli.
Intervention
Participants in both versions of the Alc-inhibition training
(Alc-IT) are, as the name suggests, trained in alcohol-
specific inhibition: pictures of alcoholic beverages will be
consistently paired with a NoGo cue, while Go cues will
be distributed among the other picture types (water, neu-
tral). In contrast, for patients in the control training group,
all three picture types will be paired equally often with
NoGo cues and Go cues (see Table 1).
 Alc-IT (50/50): the first training group will operate
with a Go/NoGo ratio of 50/50, as implemented in
prior studies [32, 33]: This original version of the
Alc-IT will include 80 alcoholic NoGo trials as well
as 80 non-alcoholic Go trials. In order to match
both Alc-IT versions in training length while keeping
the number of Alc-NoGo pairings constant, an add-
itional 80 neutral Go trials and 80 neutral NoGo tri-
als were included
 Alc-IT (75/25): the second version of the Alc-IT will
operate with a Go/NoGo ratio of 75/25. It will
equally include 80 alcoholic NoGo trials and 80
non-alcoholic Go trials, but contrary to Alc-IT
(50/50) 160 neutral Go trials will complete the set.
Both Alc-IT versions thus include the same number
of Alc-NoGo pairings and are of the same length,
but differ in their Go/NoGo ratio and thus in the
difficulty regarding inhibition control
 Control training: the control group will receive
a training that consists of 80 non-alcoholic, 80
alcoholic, and 160 neutral trials. This control
training is thus a non-specific inhibition training
which is of equal length to other two groups and
includes the same number of alcohol-related pic-
tures in it, but all pictures will appear with equal
probabilities as Go or NoGo trials while the Go/
NoGo ratio is kept at 50/50
All three versions of the inhibition training were pro-
grammed with Inquisit 5 (Version 5.0.5.0., Millisecond
Software, Inc., Seattle, WA, USA). They are based on
the script by Houben, Havermans [32], Houben, Neder-
koorn [33], which was gratefully received by the authors
and adapted to their own version. Go and NoGo cues
are represented by the letter “p” or “f” next to one of the
four corners of the alcohol, water or neutral pictures
(1047 × 1080 pixel), whereby the assignment to the let-
ters will be counterbalanced across participants. Partici-
pants will be instructed to press the space bar when a
Go cue has been displayed and to refrain from pressing
it when a NoGo cue has appeared. Each version of the
training lasts approximately 13 min and consists of 320
trials, which are presented in a randomized order. A trial
includes the simultaneous presentation of a picture and
a cue (paired in accordance with the intervention ver-
sion) and is visible on screen for 1500ms. Participants
are instructed to respond as fast as possible, unless the
picture is paired with a NoGo cue. 500 ms after the
(non)response visual feedback will be given, with a green
circle indicating a correct (non)response, and a red cross in-
dicating an incorrect (non)response. Based on data by Eberl
et al. [54], which compared learning outcome after varying
numbers of sessions of computerized training in AUD pa-
tients, participants will perform six training sessions.
Interviews and questionnaires
Demographics
Relevant demographics (e.g., age, gender, education) as
well as relevant information about past AUD treatment
or other mental health problems will be assessed.
Diagnostics
The German version of the semi-structured interview of
the Diagnostic Expert System for Psychiatric Disorders
(DIA-X, adapted to the Diagnostic and Statistical Manual
of Mental Disorders (DSM-5); [55])) specifically for AUD
will be performed by a trained member of the study team.
The original DSM-IV version was modified to meet the
DSM-5 criteria, whereby the symptom craving was added
and the question about legal issues was removed.
Alcohol use disorder and other substance use
The screening questionnaire Alcohol Use Disorders Identi-
fication Tests (AUDIT; [49]) from the World Health
Organization (WHO) consists of 10 items on recent alco-
hol use, AUD symptoms, and alcohol-related problems.
With the Alcohol Use Disorder - Scale (AUD-S;
[50]; adapted to DSM-5), self-rated AUD symptoms
Table 1 Distribution of trial types in the three training versions
Alc-IT (50/50) Alc-IT (75/25) Control training
Trial type Trial type Trial type
Picture types Go NoGo Go NoGo Go NoGo
Alcohol – 80 – 80 40 40
Water 80 – 80 – 40 40
Neutral 80 80 160 – 80 80
Total trials 320 320 320
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are measured, whereas this adapted version addition-
ally includes craving as a criteria.
To assess patients’ alcohol use in the last 90 days prior
to their current detoxification, an adapted version of the
Health and Daily Living Form (HDL; [56]) will be used,
which was also employed in a large, Swiss multicenter
study [57, 58]. Patients will be asked about their consump-
tion frequency and quantity of beer, wine, liquor and
spirits, resulting in total number of standard drinks (SD; 1
SD equates to 3 dl beer, 1 dl wine, 2 cl spirits/liquor, or 10
g of pure alcohol) consumed per day. Separate items as-
sess the PDA and the number of HDD for the last 90 days.
To measure the drinking behavior for each of the past
90 days, the Timeline Follow-back (TLFB; [59, 60])
method will be performed, which will be administered
by an interview (face-to-face at T1 or telephone at T5)
with a trained member of the study team. As in the
HDL, the amount of alcohol per day will be assessed in
standard drinks per day, but in contrast is conducted
through a guided, standardized interview. The TLFB
provides a report of drinking pattern, including PDA,
HDD and TFD.
With the Drug Use Identification Test (DUDIT; [47, 48]),
participants will be screened for substances (except nico-
tine) other than alcohol. Patients with other severe sub-
stance use and healthy controls with a problematic
substance use are not eligible for this trial (see also “Inclu-
sion/exclusion” criteria).
Alcohol-related constructs
Alcohol craving will be measured by the Obsessive Com-
pulsive Drinking Scale, (OCDS-G; [61]). The items of
the OCDS-G are divided into two subscales: control and
consequences, and drinking obsessions.
As a second measure for craving, three specific ques-
tions will be asked [57, 58], which are scored from 0
(non-existent or never) to 10 (very strongly or always):
“How strong was your urge to drink alcohol (on average)
during the past 7 days?”; “Think of the moment during the
past 7 days, in which the urge to consume alcohol was the
highest. How strong was the urge?”; and “How often did
you have the urge to drink alcohol during the past 7 days?”
Motivation to change alcohol use will be assessed
with the Stages of Change Readiness and Treatment
Eagerness Scale (SOCRATES; [62]), whereby only the
subscale Taking Steps will be used. It indexes whether
the person has already taken action to positively change
their drinking behavior.
A second measure for motivation consists of three
items on an 11-point Likert scale, summed up as Motiv-
ation [41, 63, 64]. Inspired by the framework of motiv-
ational interviewing [64], the first question “How
important is it for you not to drink alcohol? What do
you think about that at this very moment?” [63] will be
followed by the statement “I will do everything to get
my alcohol problem under control.” [64]. Third, general
self-efficacy will be assessed with one question: “How
confident are you that you will be completely abstinent
in one year from now?” [41].
A broader concept of alcohol-specific self-efficacy will
be measured with the Alcohol Abstinence Self-Efficacy
Scale (AASE-G [65]), which assesses the patients’ expec-
tations concerning their ability to remain abstinent from
alcohol in specific high-risk situations.
Positive and negative alcohol outcome expectancies
are quantified with the Comprehensive Alcohol Expect-
ancy Scale (CAEQ [66, 67]). A reduced version [67] will
be used to assess five dimensions of alcohol expectan-
cies: social assertiveness and positive affect; tension re-
duction; cognitive impairment and physical discomfort;
aggression; and sexual enhancement.
As has been done before [57, 58], Drinking Goals will
be assessed by asking the patients whether their personal
drinking goal is (1) total abstinence and hence no future
alcohol use, (2) abstinence with occasional lapses, or (3)
controlled and responsible drinking.
Finally, with a self-created Discharge Questionnaire, all
patients will be asked about occurring relapses during
their treatment. Participants will be informed that this
information is confidential and will not be shared with
the staff of the relevant hospital.
Psychopathology
General psychopathology will be assessed with the Brief
Symptom Check List, (BSCL, formerly BSI; [51, 52]),
which comprises of nine primary symptom dimensions
(e.g., depression, anxiety, hostility) and three global indi-
ces (e.g., global severity index).
Apart from this general measure, several screenings for
specific psychopathological syndromes which are often co-
morbid with AUD will be implemented: the intensity of
anxiety symptoms will be assessed with the Beck Anxiety
Inventory (BAI [68, 69]), and for qualification of the sever-
ity of depressive symptoms, the Beck Depression Inventory
(BDI-II [70, 71]) will be administered. The ADHD Self
Report Scale (ASRS-V1.1 [72, 73]) assesses symptoms of
Attention Deficit and Hyperactivity Disorder (ADHD).
The PTSD Screening Scale (PSS; [74, 75]) qualifies symp-
toms of posttraumatic stress disorder (PTSD).
Additionally, stress (due to loss or experience of nega-
tive events) and coping will be assessed with the Stress
and Coping Inventory (SCI [76]). Subjectively perceived
quality of life will be measured with three subscales (glo-
bal scale, physical and psychological health) from the
short version of the World Health Organization Quality
of Life questionnaire (WHOQOL-BREF [77, 78]).
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Traits
Relevant traits linked to AUD are of special interest:
Impulsivity will be measured with the short question-
naire Scale for Impulsive Behavior (I-8 [79]). Sensation
seeking will be qualified with the Need Inventory of
Sensation Seeking (NISS [80]), which includes two sub-
scales (need for stimulation and avoidance of rest). To
assess Antisocial Personality Disorder (ASPD), an
adapted questionnaire from the Mini-International
Neuropsychiatric Interview (M.I.N.I. [81], also employed
in the C-Surf cohort study [82]) will be used. To quan-
tify motivational systems (activation/inhibition), under-
lying behavior and affect, the Behavioral Inhibition
System/Behavioral Approach System Scales (BIS/BAS
[83]) will be used as in the C-Surf cohort study [84] in a
version adapted from the validated German version [85].
Other
Additionally, two other measures will be used: experi-
enced emotions as well as the capability of the partici-
pant to experience and regulate these emotions will be
measured with the Emo-Check [86, 87]. The Trail Mak-
ing Test A and B (TMT A & B [88]) screens for neuro-
psychological executive function by assessing visual
attention and task switching. Previous research with pre-
clinical samples indicates that executive functions could
influence the relationship between alcohol-related impli-
cit cognitions and addictive behaviors ([89, 90], but see
[54]). Consequently, the TMT will be used as a covariate
in the statistical analyses.
Experimental tasks
Both the computerized experimental tasks and response
logging are programmed and administered with E-Prime
2.0 (EP2Pro2.0.10.356, Psychology Software Tools, Sharps-
burg, PA, USA). With the picture size (344 × 400 pixel)
being equal for all three tasks, the set of alcohol-related
pictures will be matched to the individual’s drink of choice
(beer, wine, or spirits).
Go-NoGo Task (GNG)
This task measures response inhibition in both an
alcohol-specific and a neutral context. In the modified ver-
sion of Stein et al. [25], eight pictures of alcoholic bever-
ages (beer, wine, or spirits, according to the participants
drink of choice) and eight neutral beverages (water) are
presented on screen at a presentation rate of 1 Hz. The
pictures are displayed on-screen for 900ms and the inter-
stimulus interval is 100ms. Participants are instructed to
click a button as soon as a stimulus appears on screen
(Go trial) unless the same stimulus appears twice in a row
(NoGo trial). Each of the 16 pictures will be presented 60
times during the task: 52 times as a Go trial and eight
times as a NoGo trial, resulting in a Go/NoGo ratio of 6.5.
This ratio is intended to establish a high tendency to re-
spond, making action restraint difficult. In total, the whole
experiment thus includes 960 trials (416 neutral Go trials,
416 alcohol-related Go trials, 64 neutral NoGo trials, and
64 alcohol-related NoGo trials), which are presented in a
pseudorandomized order, controlling for position, sequen-
tial order, and requiring a minimum of two Go trials be-
tween two NoGo trials. Half way through, participants are
allowed a pause of a self-determined length. The whole
task takes approximately 18min to complete.
Stop-Signal Task (SST)
As a second measure of response inhibition, a Stop-Signal
Task (SST) will be performed, which includes four pic-
tures of alcoholic beverages located inside a building and
four neutral pictures of objects located outside. After a fix-
ation cross, which lasts 460ms, the individual pictures will
appear on a computer screen and participants will be
instructed to press the button “a” (left) or “l” (right) as
soon as possible to indicate whether the picture was taken
inside (confounded with alcohol-related content) or out-
side a building (confounded with neutral content). During
instructions, this pairing of location (inside, outside) and
content (alcohol, neutral) is not mentioned. An exception
to the rule is to be made when an auditory stop signal oc-
curs (NoGo; 25% of the trials). This stop signal starts with
a delay of 100, 200, or 300ms (each comprising one third
of NoGo trials) after stimulus onset. As this stop signal
appears after the picture, and not simultaneously with it,
as during the GNG or the training, task performance in
the SST depends on action cancellation and thus mea-
sures a slightly different aspect of response inhibition.
After completion of two practice blocks each, two test
blocks comprising 240 trials each (180 Go and 60 NoGo
trials) will be completed. The key allocation is counterba-
lanced, and the order of trials is pseudorandomized. As an
indicator of response inhibition, the stop-signal reaction
time (SSRT) will be computed for alcohol-related and
non-alcoholic pictures according to the algorithm de-
scribed in Houben, Havermans [32].
Implicit Association Test (IAT)
Implicit associations between alcohol and affective attri-
butes will be measured with an alcohol-specific IAT [91].
In a valence IAT, pictures of alcoholic beverages are either
paired with a positive (e.g., funny) or a negative (e.g., dull)
word. Participants must classify if a stimulus either be-
longs to one of the target categories (pictures of alcoholic
drinks vs. waters) or to one of the affective categories
(positive vs. negative verbs) with response buttons on a
keyboard (left “a” vs. right “l”). The eight alcoholic and
eight water pictures are the same as in the inhibition
training (see “Stimulus material”). In accordance with pre-
vious preclinical studies [32, 33], the affective categories
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consist of eight positive (happy, jolly, energetic, funny, so-
ciable, attractive, cheerful, smart) and eight negative (dull,
miserable, sick, depressed, unhappy, disgusting, angry,
foolish) attributes. The German translation (glücklich,
ausgelassen, dynamisch, lustig, gesellig, attraktiv, fröhlich,
klug, lustlos, miserabel, übel, deprimiert, unglücklich,
widerlich, wütend, dumm) were validated by three inde-
pendent native-English speakers. During “alcohol-positive”
blocks, stimuli from the categories alcohol and positive
are represented by one response button, while water and
negative attributes require pressing the other response
button. Contrary to this, during “alcohol-negative” blocks,
stimuli from the alcohol and negative category share one
response button, while water and positive attributes are
indicated with the other response button. Based on the ra-
tionale that associated concepts (e.g., alcohol and positive
attributes) are more easily combined than unrelated con-
cepts (e.g., alcohol and negative attributes), reaction time
differences between these two blocks can be used to assess
the association strength between target and affective cat-
egories. According to the developers [91], a significant dif-
ference in reaction time between both examples would
indicate strong positive associations towards alcohol.
For this study, task development in E-Prime was based
on an adapted version used by Egenolf et al. [92]. To
control for sequence effects of the starting target con-
cepts (alcohol, water) both IAT versions consist of 14
blocks. All blocks are interposed with rest periods of a
self-determined length. Initially, and whenever key as-
signment changes, participants will undergo two or three
practice blocks consisting of 16 trials each: First, they
classify the target concepts (alcohol, water) and/or the
affective categories (positive, negative) to left (“a”) and
right (“l”). Second, they practice the combination of target
concepts and affective categories. After these blocks, a
longer test block of 64 trials follows (for an overview of
the procedure, see Additional file 3). To remind partici-
pants of the current mapping rule, category labels will be
presented in the upper two corners of the screen. Stimuli
will appear on-screen for maximum 1750ms or until an
answer is given, followed by feedback (for 200ms). The in-
terstimulus interval will be 250ms. The IAT consists of
416 trials and lasts 10–20min depending on the individ-
ual’s speed and duration of rest periods. Reaction time
analyses will be conducted according to the improved
scoring algorithm by Greenwald, Nosek et al. [93].
Procedure patients
The study duration from the admission of the first par-
ticipant to the last participant’s follow-up is 36–40
months. The duration of participation for an individual
study participant is commonly 14–16months depending
on the duration of the inpatient stay. Apart from the main
study, the substudies cortisol and EEG are integrated in
the main study procedure. During the standard inpatient
treatment, the assessments T1 to T4 will take place. After
discharge, and at each of the three follow-up time points,
questionnaires will be sent to each participant, and they
are additionally contacted by telephone (see also Fig. 1).
For an overview about the single time points, consult the
Standard Protocol Items: Recommendations for Inter-
national Trials (SPIRIT) Figure (Fig. 2). The SPIRIT
Checklist is also provided as Additional file 4.
Recruitment
At treatment admission, all patients’ medical records will be
screened for eligibility for participation in the study. If all in-
clusion criteria and no apparent exclusion criteria are ful-
filled, the patient will be invited to an information
appointment during the first treatment week. Therein, the
study will be explained, questions will be answered, and
lastly, the person is asked if they would participate. For
those having given informed consent, we will screen for
other severe substance use disorders using the DUDIT [47].
T1: Inclusion and baseline assessment
During the second treatment week, a member of the
study team will conduct an interview to confirm the
AUD diagnosis (DIA-X adapted to DSM-5 criteria; [55]).
To assess the drinking quantity of the 90 days prior to
detoxification, the TLFB interview will be conducted [59,
60]. Furthermore, a psychological assessment with a test
battery consisting of questionnaires will also take place
at this time point.
Randomization and blinding
Patients will be randomly assigned to one of the three
study arms, with the aim of generating equally sized
groups. Block randomization with variable block sizes will
be stratified according to gender and age (age groups: 18–
25, 26–35, 36–45, 46–55 and 56–60 years). The stratified
randomization list will be generated with Matlab (Version
2017a, MathWorks, Inc., Natick, MA, USA), and stored in
one document. The participants’ allocation to a study arm
will be done by an independent investigator who will ad-
ministrate and conceal the list. Thus participants, investi-
gators, care providers and members of the study team will
be blind to the allocation schedule.
T2: Pre-training assessment
Prior to the training, all subjects will undergo an assess-
ment including a series of questionnaires as well as ex-
perimental tests measuring implicit associations towards
alcohol (IAT) and inhibitory control (GNG, SST). This
will take place at the end of the third treatment week. A
total of 60 patients (for the EEG substudy) will addition-
ally be assessed with multi-channel EEG while completing
the experimental tasks. As the intense confrontation with
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alcohol pictures may lead to tension and induce craving in
patients with AUD, we will monitor our participants’
stress and craving on an 11-point Likert scale (0 = not at
all, 10 = very strong) immediately before and after the as-
sessment. In the case of significant stress or craving levels,
the medical staff on duty will be contacted and informed.
Fig. 2 Enrollment, interventions and assessments at each time point for patients in the INTRA study. A schematic outline of the enrollment,
interventions and assessments that each participant of the main INTRA study will undergo. AASE-G Alcohol Abstinence Self-efficacy Scale –
German version, Alc-IT alcohol-inhibition training, ASPD antisocial personality disorder, ASRS-V1.1 Adult ADHD Self-Report Scale, AUDIT Alcohol Use
Disorders Identification Test, AUD-S Alcohol Use Disorders Scale, BAI Beck Anxiety Inventory, BDI-ll Beck’s Depression Inventory, BIS/BAS Behavioral
Inhibition System/Behavioral Approach System Scale, BSCL Brief Symptom Check List, CAEQ Comprehensive Alcohol Expectancy Questionnaire; Craving
(Likert scales), DIA-X Diagnostic Expert System for Psychiatric Disorders, Emo-Check Assessment of Emotion and Emotion regulation, GNG Go-NoGo
Task, HDL Health and Daily Living Form, IAT Implicit Association Test, IT inhibition training, I-8 Scale for Impulsive Behavior, Motivation (Likert scales),
NISS Need Inventory of Sensation Seeking, OCDS-G Obsessive Compulsive Drinking Scale – German version, PSS PTSD Symptom Scale, SCI Stress and
Coping Inventory, SOCRATES Stages of Change Readiness and Treatment Eagerness Scale, SST Stop-Signal Task, TLFB Timeline Follow-back, TMT Trail
Making Test A and B, WHOQOL-BREF WHO Quality of Life Scale (brief version), −T1 before treatment admission, T1 baseline, T2 pre-training, T3 post
training, T4 discharge, T5 3-month follow-up, T6 6-month follow-up, T7 12-month follow-up
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Training (intervention)
During weeks 4 and 5 of the treatment, all patients will
undergo six short training sessions according to their al-
located training version (Alc-IT (75/25), Alc-IT (50/50)
or control group, either in the morning or afternoon).
All training sessions will be distributed over 2 weeks,
performed in a group setting, and monitored by a mem-
ber of the study team. At the beginning of the first ses-
sion, participants undergo a short practice version to
confirm that they understood the task. Before and after
each training session, stress and craving will be assessed
(see also T2). At the end of each training session, the
study member will take note of the participants’ reaction
time and error rate, with the aim to maintain motiv-
ation. In order to assess saliva cortisol concentration for
the cortisol substudy, saliva samples of 80 patients of the
Suedhang Hospital will be collected before and after the
first training.
T3: Post-training assessment
One to 4 days after the last training session, patients will
undergo the same assessment as in T2 (including ques-
tionnaires and experimental tasks). The 60 participants
of the EEG substudy again participate in the EEG re-
cording during the experimental tasks. Before and after
the measurement, self-reported stress and craving will
be assessed (see also T2).
Discharge assessment (T4)
Upon discharge from inpatient treatment, psychological
parameters are measured again with the questionnaires
used at previous time points. At the end of T4, the pro-
cedure for the follow-up measurements will be explained.
3-month follow-up (T5)
Three months after discharge, all participants will be
contacted by telephone. The primary outcome variables
will be assessed in a short telephone interview, and an
appointment for the TLFB interview will be arranged if
it cannot be carried out at the time of the call. Parallel
to this telephone interview, a questionnaire battery will
be sent to the patients’ private address.
6- and 12-month follow-up (T6, T7)
Six (T6) and 12 (T7) months after discharge, a similar
procedure as in T5 will be performed. At both time
points, participants will receive the questionnaire battery
by post and will be called by telephone to assess the
most significant outcome variables.
Procedure to enhance response rates at the follow-up
assessments (T5, T6, T7)
To achieve high response rates, a meticulous plan will
be pursued for each follow-up assessment: Participants
will be contacted by telephone starting 10 days prior to
the target day (90, 180 and 365 days after discharge) to
announce the upcoming assessment. Should three con-
tact attempts fail, a text message is sent. In case of no
response, they are called another seven times, and a set
of questionnaires will be sent shortly before the target
day. If these questionnaires are not returned within 15
days, they are called another 10 times. If provided, an
additional email is sent. This procedure will be repeated
if the patient has been reached yet no questionnaires are
returned. If it is possible to talk to the participant at any
time during the process, the most important primary
outcome variables are queried. This entails that at least
the most important variables can be collected, even if
the participant does not return the questionnaires. As a
last resort, a voluntarily provided contact of the partici-
pant is called. If none of these attempts succeed, the
follow-up assessment will be terminated. Participants re-
ceive 20 CHF for each follow-up assessment.
Procedure for substudies
Cortisol substudy
Inclusion and exclusion criteria for the substudy match
those of the main study. The first 80 patients who are
recruited in the Suedhang Hospital will be additionally
asked to participate in the cortisol substudy, which in-
volves collecting a salvia-cortisol sample before and after
the first training session.
EEG substudy
As this involves more time-consuming measurements at
T2 and T3, a two-level recruitment-process will be imple-
mented: Inclusion and exclusion criteria for the substudy
match those of the main study. However, recruitment of
these participants will additionally depend on their mental
capacity, age and gender balance, and their available time
considering the clinic’s already demanding agenda. If
eligible patients are interested in participating, additional
information concerning EEG measurements will be pro-
vided, and an additional informed consent for this sub-
study will be signed. When 20 participants per training
version are included in this substudy, the recruitment pro-
cedure will be stopped. Patients enrolled in the EEG sub-
study will receive a monetary compensation of 50 CHF per
measurement.
Procedure for healthy controls
Interested potential participants will receive the partici-
pant’s information and informed consent to read. If eli-
gible for the study, a member of the study team will
verify the inclusion and exclusion criteria during a screen-
ing. If a person is included in the study, written informed
consent will be obtained, and the subject will undergo the
same experimental tasks (IAT, GNG, SST) and a similar
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questionnaire battery as the patient sample at T1 (for an
overview, see Additional file 5). Questionnaires and behav-
ioral data during tasks will be collected from 30 healthy
controls, the same measurement will be collected from
another 20 additional healthy controls while an EEG is re-
corded during the experimental tasks (T2 and T3).
Healthy controls without an EEG will receive no monetary
compensation, whereas subjects in the EEG group will re-
ceive 30 CHF for any EEG-related inconvenience.
Data collection and statistical analysis
Questionnaires
Will be assessed by using paper and pencil and will then
be entered into SPSS (Version 24.0, IBM SPSS Statistics
for Windows, IBM Corp, Armonk, NY, USA). Behavioral
data will be collected with E-Prime 2.0 (EP2Pro2.0.10.356,
Psychology Software Tools, Inc., Sharpsburg, PA, USA).
EEG data
Electrophysiological data will be recorded with BrainVision
Recorder (Version 2.0, Brain Products GmbH, Gilching,
Germany) using 64 active electrodes distributed across the
scalp according to the extended 10/10 system. The sam-
pling rate is 500 Hz, online filters are set to 0.016Hz (high-
pass) and 250Hz (low pass), impedances are kept below 20
kΩ, FCz will serve as on-line reference. Each participant
will first undergo a 5-min resting state EEG with alternat-
ing epochs of eyes open and eyes closed. Then, the experi-
mental test battery of the T2 and T3 assessment,
consisting of a Go-NoGo Task (GNG), an Implicit Associ-
ation Test (IAT) and a Stop-Signal Task (SST), will be ad-
ministered while the EEG is still recorded. For details
about the tasks, please see section “Experimental tasks.”
Cortisol data
Saliva samples for cortisol analyses will be stored at − 80 °C.
Statistics
All statistical analyses will be conducted by the members
of the study team. The main analyses of the training effect
will be carried out after data collection is completed to
maintain the study’s double-blind design. All behavioral
and questionnaire variables will be tested for normal distri-
bution (Kolmogorov-Smirnov test: p > 0.1, for all variables)
.
Main study
Training effects on our primary outcome measures
(PDA and HDD at 3-month follow-up) will be assessed
with a 2 × 3 analysis of variance (ANOVA) with the fac-
tors time point (T1, T5) and training group (Alc-IT (50/
50), Alc-IT (75/25) or control). Further, a Cox regression
will be computed to predict the effect of the intervention
on TFD (at 3-month follow-up).
Training effects on experimental test parameters will be
assessed with a 2 × 2 × 3 repeated measures ANOVA with
the factors measurement point (T2, T3), time of day (morn-
ing, afternoon) and training group (Alc-IT (50/50), Alc-IT
(75/25) or control). Where Mauchly’s test of sphericity indi-
cates heterogeneity of covariance, we will verify repeated
measures results with Greenhouse-Geisser corrections.
EEG substudy
All raw EEG data will be pre-processed with BrainVision
Analyzer (Version 2.0, Brain Products GmbH, Gilching,
Germany) according to current standards including ICA-
based correction of eye-movement artefacts, artefact rejec-
tion and application of band-pass filtering (see e.g., [94–
96]). Event-related potentials (ERPs) will be computed for
each stimulus type in the three experiments (IAT, GNG,
SST). Epochs from 500ms (pre-stimulus) to 1500ms
(post-stimulus) will be averaged separately for each stimu-
lus type and measurement point (T2 and T3). ERPs will
subsequently be statistically compared for overall ampli-
tude (i.e., global field power, GFP) and topography. For
each ERP, GFP [97] will be calculated as the standard devi-
ation across electrodes, thus measuring momentary global
signal strength regardless of topographic modulations.
GFP values for each point in time will be extracted and
compared (T2 vs. T3) with nonparametric randomization
tests, which simultaneously control for multiple compari-
sons. The analyses will be conducted using the Ragu soft-
ware [98, 99].
To inspect for topographic differences between ERPs
measured before and after the training, a topographic
analysis of variance (TANOVA) [100] will be computed
in Ragu. Here, dissimilarities of electric field topograph-
ies are identified with a nonparametric randomization
test. A significant finding in the TANOVA indicates that
activation in underlying brain structures vary in relation
to the factor under investigation. Significant TANOVA
results will be further explored with the standardized
low-resolution electromagnetic tomography (sLORETA)
source analysis method [101]) to determine which brain
regions vary in activation in relation to stimulus type
and/or measurement time (T2 vs. T3).
Based on prior findings, our ERP analyses will focus
on the timeframe from about 150 to about 850 ms. Exact
timeframes will be defined based on components as vis-
ible in GFP-curves or by microstate analyses [102, 103].
Following earlier research, care will be taken to include
the N2 and P3 components in case of the GNG [25, 26]
and the N2, P3, N4 and LPP components in case of the
IAT (e.g., [104–106]).
Cortisol substudy
Salivary cortisol concentrations are determined by a com-
mercially available chemiluminescence immunoassay
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(CLIA; IBL, Hamburg, Germany). Inter- and intra-assay
coefficients of variation are both below 8%. For biochem-
ical analyses of free cortisol concentration, saliva samples
will be thawed and spun at 3000 rpm for 10min to obtain
0.5–1.0ml of clear saliva with low viscosity.
Power calculation
The intended sample size was calculated with G*Power
(Version 3.1.5, Heinrich-Heine-University Duesseldorf,
Dusseldorf, Germany). In a-priori analyses (1−β = 0.8,
α = 0.05), slightly reduced expected effect sizes were en-
tered compared to earlier studies because of the add-
itional manipulations concerning different training
versions and time of training. For the 2 × 3 ANOVA to
examine the training effects on the primary outcome
measures PDA and HDD (with an expected effect size of
f = 0.2 based on earlier studies [32]), a total sample size
of n = 244 is needed. For the analyses of the training’s ef-
fect on TFD (the third primary outcome, estimating a
small to medium effect size of w = 0.25 based on earlier
studies [37], and df = 3), G*Power indicated a total sam-
ple size of n = 174 for the Cox regression. For the 2 ×
2 × 3 repeated measures ANOVA examining training ef-
fects on experimental parameters and also taking into
account the effects of time of day of the training (expect-
ing small to medium effects of f = 0.15 and correlations
of 0.4 among repeated measures based on earlier studies
[107]), the necessary sample size was n = 180. Consider-
ing the necessary power for all analyses and similar sam-
ple sizes in all study arms (82 per intervention group), a
total of 246 patients will be recruited.
Discussion
The results of the INTRA study should provide evidence
for the efficacy of an add-on treatment to specialized
standard care for AUD. In contrast to previous non-
clinical studies [32, 33], this double-blind RCT investi-
gates the effect of a computerized inhibition training in
inpatients with AUD. It includes important measures of
alcohol consumption and follow-up periods of up to 1
year. With respect to working mechanisms, the study in-
cludes a thorough assessment of inhibitory control func-
tions and alcohol-specific implicit associations on both a
behavioral and neurophysiological level. Through this in-
vestigation, we hope to expand current knowledge about
the role of inhibitory functions in AUD and extend pre-
vious findings about the effects of this training [25, 26,
32–37]. In order to describe the patients’ baseline mea-
sures, including possible inhibitory deficits, and to better
interpret the observed modifications, the patients’ be-
havioral and neurophysiological data will be compared
to healthy controls.
In additional to these proximal findings, the effect of
the intervention will also be analyzed longitudinally. At
3-, 6- and 12-month follow-ups, important measures of
alcohol consumption, our primary outcome, as well as
psychological parameters will be collected to inform us
about the time after inpatient treatment. Finally, this
trial will investigate whether endogenous cortisol might
increase possible effects of the inhibition training.
As one potential limitation, one could argue that pa-
tients in the control training group undergo a non-
context-specific inhibition training, which might en-
hance their general inhibitory capacities. The choice of
the control group is, therefore, very strict and could lead
to an underestimation of the effect of the inhibition
training. However, control conditions used in previous
non-clinical studies [32, 33] consistently paired alcohol
stimuli with Go responses and tended to enhance alco-
hol consumption in these samples. Therefore, due to
ethical considerations, we opted against this control con-
dition in a clinical sample.
Overall, the current double-blind RCT is the first
study to investigate the effect of an inhibition training in
an inpatient treatment setting in patients with AUD. It
allows a detailed proximal and distal evaluation of be-
havioral, psychological and neurophysiological processes
in AUD and of the efficacy of the inhibition training. We
therefore hope that it might ultimately contribute to the
improvement of evidenced-based AUD treatment.
Trial status
The trial is currently in the data collection phase, which is
planned to end in March 2020.
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